Evidence map›Paper›PMID 23441162›Full record

ArticlePloS one2013

HLA-B35 and dsRNA induce endothelin-1 via activation of ATF4 in human microvascular endothelial cells.

Stefania Lenna, Izabela Chrobak, G Alessandra Farina, Fernando Rodriguez-Pascual, Santiago Lamas, Robert Lafyatis, Raffaella Scorza, Maria Trojanowska

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. ATF4 is a novel regulator of MCP-1 in microvascular endothelial cells.Journal of inflammation (London, England) · 2015
    Article
  11. Review
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Stefania LennaArthritis Center, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Izabela Chrobak
G Alessandra Farina
Fernando Rodriguez-Pascual
Santiago Lamas
Robert Lafyatis
Raffaella Scorza
Maria Trojanowska
Boston University · USUniversidad Autónoma de Madrid · ESUniversity of Milan · IT

Funding

Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesisP50AR060780 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LAFYATIS, ROBERT A. · 2011 to 2021
$14.9M
The molecular mechanisms of fibrosisR01AR042334 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TROJANOWSKA, MARIA · 1994 to 2018
$5.2M
Innate immunity in dermal fibrosis and systemic sclerosisR01AR051089 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LAFYATIS, ROBERT A. · 2005 to 2015
$2.8M
Interplay between Type I IFN and TGF-beta signaling in systemic sclerosisR03AR062721 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARINA, GIUSEPPINA ALESSANDRA · 2012 to 2014
$240k
NIAMS NIH HHS P50 AR060780NIAMS NIH HHS R01 AR042334NIAMS NIH HHS R01 AR051089NIAMS NIH HHS R03 AR062721
6 · The paper itself

Abstract

Endothelin 1 (ET-1) is a key regulator of vascular homeostasis. We have recently reported that the presence of Human antigen class I, HLA-B35, contributes to human dermal microvascular endothelial cell (HDMEC) dysfunction by upregulating ET-1 and proinflammatory genes. Likewise, a Toll-like receptor 3 (TLR3) ligand, Poly(I:C), was shown to induce ET-1 expression in HDMECs. The goal of this study was to determine the molecular mechanism of ET-1 induction by these two agonists. Because HLA-B35 expression correlated with induction of Binding Immunoglobulin Protein (BiP/GRP78) and several heat shock proteins, we first focused on ER stress and unfolded protein response (UPR) as possible mediators of this response. ER stress inducer, Thapsigargin (TG), HLA-B35, and Poly(I:C) induced ET-1 expression with similar potency in HDMECs. TG and HLA-B35 activated the PERK/eIF2α/ATF4 branch of the UPR and modestly increased the spliced variant of XBP1, but did not affect the ATF6 pathway. Poly(I:C) also activated eIF2α/ATF4 in a protein kinase R (PKR)-dependent manner. Depletion of ATF4 decreased basal expression levels of ET-1 mRNA and protein, and completely prevented upregulation of ET-1 by all three agonists. Additional experiments have demonstrated that the JNK and NF-κB pathways are also required for ET-1 upregulation by these agonists. Formation of the ATF4/c-JUN complex, but not the ATF4/NF-κB complex was increased in the agonist treated cells. The functional role of c-JUN in responses to HLA-B35 and Poly(I:C) was further confirmed in ET-1 promoter assays. This study identified ATF4 as a novel activator of the ET-1 gene. The ER stress/UPR and TLR3 pathways converge on eIF2α/ATF4 during activation of endothelial cells.

Indexed as

Activating Transcription Factor 4AdultAgedAnimalsCells, CulturedeIF-2 KinaseEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressEndothelial CellsEndothelin-1Enzyme ActivationFemaleGene Expression RegulationHLA-B35 AntigenHumansJNK Mitogen-Activated Protein KinasesActivating Transcription Factor 4eIF-2 KinaseEndoplasmic Reticulum Chaperone BiPEndothelin-1HLA-B35 AntigenHSPA5 protein, humanHspa5 protein, mouseJNK Mitogen-Activated Protein KinasesNF-kappa BPoly I-CProto-Oncogene Proteins c-junRNA, Double-StrandedRNA, Messenger

Identifiers

PMID23441162
PMCPMC3575387
OpenAlexW2091464202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.